jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Piles - Large Biopsy 3-6 cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Histology of hemorrhoidal tissue.

₹666₹951

30% OFF

Piles - Large Biopsy 3-6 cm: Comprehensive Medical Test Information Guide

  • Section 1: Why is it done?
    • Test Description: A large tissue biopsy (3-6 cm) collected from hemorrhoidal lesions or suspicious anal masses to obtain histopathological examination. This procedure involves removing a larger tissue specimen than standard biopsies to allow comprehensive microscopic analysis of cellular composition, tissue architecture, and identification of malignant or benign pathology.
    • Primary Indications: • Suspected malignancy in hemorrhoidal tissue or anal lesions • Large, rapidly growing hemorrhoidal masses requiring definitive diagnosis • Atypical hemorrhoids not responding to conservative treatment • Differentiation between benign hemorrhoids and malignant tumors • Evaluation of ulcerated or friable hemorrhoidal tissue • Identification of squamous cell carcinoma or other malignancies • Assessment of inflammatory bowel disease involving hemorrhoidal tissue • Investigation of persistent anal bleeding with suspicious findings
    • Typical Timing and Circumstances: • Performed during anoscopy or colonoscopy when suspicious lesions are identified • Usually scheduled after initial clinical examination and imaging if needed • Typically performed in outpatient endoscopy units or specialized proctology clinics • May be urgent if malignancy is suspected • Often performed immediately during diagnostic procedures to prevent additional visits • Timing coordinated with patient preparation and anesthesia requirements
  • Section 2: Normal Range
    • Reference Findings: • Normal/Benign: Histology showing typical hemorrhoidal vascular tissue with normal angiodysplasia, intact mucosa, absence of dysplasia or malignant cells • Specimen Size: 3-6 cm tissue adequate for comprehensive analysis • Tissue Adequacy: Sample contains sufficient mucosa, submucosa, and surrounding tissue for diagnostic evaluation
    • Normal Histological Features: • Dilated vascular channels lined by normal endothelium • Intact mucosa without ulceration • Normal submucosa and muscle layers • No dysplasia or atypia • No evidence of malignancy • Normal inflammatory response (minimal to absent) • Intact epithelial lining without erosion
    • Interpretation Guide: • Negative for Malignancy: Benign histology consistent with hemorrhoids—confirms diagnosis and guides conservative management • Positive for Malignancy: Presence of abnormal cells, dysplasia, or carcinoma—requires urgent treatment and staging • Borderline/Dysplastic: Features suggesting potential malignant transformation—may require repeat biopsy or enhanced surveillance
  • Section 3: Interpretation
    • Benign Findings (Negative for Malignancy): • Uncomplicated internal or external hemorrhoids • Confirms benign nature of the lesion • Supports conservative management approach • No urgent intervention required • Normal follow-up with standard hemorrhoid management protocols
    • Inflammatory Changes: • Increased lymphocytic infiltration or eosinophilic inflammation • May indicate inflammatory bowel disease or infectious etiology • Suggests need for additional investigations • May require targeted treatment for underlying inflammatory condition • Correlation with clinical symptoms essential
    • Dysplastic Changes (High-Grade or Low-Grade): • Presence of cellular atypia and architectural distortion • Increased nuclear-to-cytoplasmic ratio • Abnormal mitotic figures • May progress to malignancy if untreated • Requires close follow-up and possible repeat biopsy • Consider more aggressive treatment options
    • Malignant Findings (Positive for Malignancy): • Squamous cell carcinoma (most common in anal region) • Adenocarcinoma or other histological types • Requires immediate staging with imaging (CT/MRI) • Urgent oncology referral recommended • Treatment planning includes surgery, chemotherapy, or radiation • Prognosis dependent on grade, stage, and histological type
    • Factors Affecting Interpretation: • Specimen handling and fixation quality • Adequacy of tissue sampling (larger biopsies provide better diagnostic accuracy) • Prior treatments or interventions affecting tissue architecture • Patient's immune status and inflammatory conditions • Presence of infection or inflammatory bowel disease • Pathologist expertise and quality of microscopic examination • Ancillary studies (immunohistochemistry) if needed for definitive diagnosis
  • Section 4: Associated Organs
    • Primary Organ System: • Lower Gastrointestinal Tract (Rectum and Anal Canal) • Hemorrhoidal Vascular Plexus (Superior and Inferior Hemorrhoidal Veins) • Anoderm (Specialized mucosa of anal canal)
    • Associated Diseases and Conditions: • Internal and External Hemorrhoids • Anal Squamous Cell Carcinoma • Anal Adenocarcinoma • Anal Melanoma • Crohn's Disease affecting anal region • Ulcerative Colitis with anal involvement • Anal Fissures with atypical features • Anal Fistulas with tissue involvement • Human Papillomavirus (HPV)-related lesions • Anal Polyps • Recurrent Anal Infections or Abscesses
    • Complications of Abnormal Results: • Malignant Progression: Dysplasia may advance to invasive carcinoma • Metastatic Disease: Anal cancers can spread to lymph nodes, liver, and distant sites • Sphincter Dysfunction: Large lesions or treatments may cause continence problems • Chronic Pain and Bleeding: Persistent or worsening hemorrhoidal symptoms • Infection: Risk of secondary bacterial or fungal infection • Recurrence: Malignant lesions may recur locally or systemically • Treatment-Related Complications: Surgery, radiation, or chemotherapy side effects
    • Related Systems Affected by Malignancy: • Regional Lymph Nodes (inguinal and internal iliac) • Liver (potential metastatic site) • Lungs (distant metastatic potential) • Bones (osseous metastases) • Urogenital System (direct extension risk) • Rectum (proximal extension)
  • Section 5: Follow-up Tests
    • If Benign Findings (Negative for Malignancy): • Clinical follow-up at 4-6 weeks to assess symptom resolution • Repeat imaging only if symptoms persist or worsen • Standard surveillance colonoscopy per guidelines (typically every 5-10 years) • No additional biopsies required unless new symptoms develop • Monitoring for symptoms of recurrent bleeding or mass
    • If Dysplastic Findings: • Repeat biopsy in 3-6 months to monitor progression • Anoscopy every 6-12 months with targeted biopsies • HPV testing if HPV-associated dysplasia suspected • Consider excisional treatment (wide local excision) if high-grade dysplasia • Enhanced imaging (ultrasound or MRI) to assess local extension • Discussion of risk-benefit of surgical versus conservative management
    • If Malignancy Confirmed: • Urgent Imaging Studies: - CT chest/abdomen/pelvis for staging and metastatic evaluation - MRI pelvis for local tumor extent and nodal involvement - PET-CT if high-grade or advanced disease suspected • Oncology Referral: Immediate consultation for treatment planning • CEA Level: Baseline carcinoembryonic antigen for monitoring • Lymph Node Assessment: Imaging or ultrasound-guided biopsy if needed • Baseline Blood Work: Complete metabolic panel, liver function tests • Follow-up Anoscopy: Post-treatment surveillance every 3-6 months initially
    • If Inflammatory Findings: • Colonoscopy to evaluate entire colon for inflammatory bowel disease • Inflammatory Markers: CRP, ESR levels • Fecal Calprotectin if IBD suspected • Infectious Disease Workup: Culture, special stains if infection indicated • Immunological Studies: If autoimmune etiology considered • Repeat biopsy if symptoms persist despite treatment
    • Long-Term Surveillance Recommendations: • After Treatment for Malignancy: Every 3 months for first year, then every 6 months for years 2-5, then annually • Clinical Examination: Regular digital rectal exams and anoscopy • Imaging Surveillance: Annual imaging for 3-5 years if high-risk features • Patient Self-Monitoring: Education on warning symptoms requiring urgent evaluation
  • Section 6: Fasting Required?
    • Fasting Requirement: NO (General Fasting Not Required) This is a tissue biopsy procedure and does not typically require fasting for the biopsy itself. However, specific preparation depends on whether the procedure is performed as standalone or during colonoscopy/anoscopy.
    • Patient Preparation Requirements: • Bowel Preparation: - If performed during anoscopy alone: Enema morning of procedure preferred - If performed during colonoscopy: Full bowel prep with polyethylene glycol or similar agents - Clear liquids usually allowed up to 2 hours before procedure • Rectal Cleansing: Patient should empty bowels before procedure • Anal Hygiene: Clean anal area thoroughly the morning of procedure
    • Medications to Avoid or Adjust: • Anticoagulants: Warfarin, dabigatran—typically continue but confirm with physician • Antiplatelet Agents: Aspirin, clopidogrel—usually continued unless high bleeding risk; discuss with gastroenterologist • NSAIDs: Hold 5-7 days before procedure if possible to reduce bleeding risk • Prophylactic Antibiotics: May be given if high endocarditis risk or immunocompromised • Sedatives: Avoid alcohol and sedating medications day before and day of procedure • Insulin: Adjust dosing if fasting not required; consult diabetes team if extensive NPO required
    • Anesthesia/Sedation Considerations: • Local Anesthesia: Usually sufficient; no fasting required • Conscious Sedation: May be used; requires NPO (nothing by mouth) 6 hours prior • General Anesthesia: Requires NPO 8 hours (solids) and 2 hours (clear liquids) • Confirm anesthesia plan with facility at least 48 hours before procedure
    • Additional Pre-Procedure Instructions: • Informed Consent: Review risks including bleeding, infection, pain, rare perforation • Medical History: Disclose allergies (especially lidocaine or other local anesthetics), bleeding disorders, cardiac conditions • Bring Identification: Valid photo ID and insurance cards • Transportation: Arrange designated driver if sedation or general anesthesia planned • Clothing: Wear loose, comfortable clothing; remove metal objects • Contact Lens/Hearing Aid: May need to remove if sedation planned • Recent Labs: Blood type and screen may be required if significant bleeding risk
    • Post-Procedure Care Instructions: • Resume Normal Diet: After procedure once alert; start with light foods • Hydration: Drink adequate fluids to prevent dehydration • Activity: Avoid strenuous activity for 24-48 hours • Bleeding Management: Minor anal bleeding common; report excessive bleeding • Pain Control: Use prescribed analgesics as directed; avoid NSAIDs if high bleeding risk • Bowel Movements: Report severe abdominal pain or fever immediately • Follow-up Appointment: Schedule follow-up to review pathology results (typically 7-10 days)

How our test process works!

customers
customers